Pharvaris Reports Positive Late-Stage Trial Results for HAE Drug
Pharvaris (PHVS) saw its stock rise more than 10% in premarket trading after announcing positive results from a late-stage trial of deucrictibant XR, its lead drug candidate. The medication met the primary endpoints for treating hereditary angioedema (HAE), a rare genetic disorder marked by episodes of swelling. The success marks an important milestone as it brings the company closer to potential regulatory approval and commercialization. HAE is a condition with limited treatment options, making deucrictibant XR's performance particularly significant in this niche market. Investors responded positively to the news, reflecting optimism about Pharvaris' future prospects.
Tickers: $PHVS